GlassScriptPhysician profile
Nancy Briley Walker
NPI 1235279043
$1,923.38
in general payments reported to CMS, 2019-2025
33 companies · $635 in 2025
The $635 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $679 · 2020: $150 · 2021: $55.94 · 2022: $36.20 · 2023: $137 · 2024: $230 · 2025: $635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,002.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,002.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $297.74 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $282.80 | 2023-2025 | Vraylar |
| Lilly USA, LLC | $117.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $111.54 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $108.18 | 2019-2025 | Gardasil 9, Capvaxive |
| Optinose US, INC. | $95.47 | 2019 | |
| Janssen Biotech, INC. | $72.33 | 2022-2024 | Tremfya |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $66.96 | 2025 | Caplyta |
| Pfizer INC. | $58.17 | 2019 | |
| Sanofi-Aventis U.S. LLC | $51.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.82 | 2019-2024 | Jardiance |
| Currax Pharmaceuticals LLC | $49.69 | 2020-2025 | Contrave |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $46.24 | 2020-2025 | Xifaxan, Trulance, Relistor |
| E.R. Squibb & Sons, L.L.C. | $44.17 | 2021 | |
| Amgen INC. | $41.22 | 2019-2023 | Evenity, Prolia |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $39.63 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $37.03 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $36.66 | 2019-2020 | |
| Exact Sciences Corporation | $36.21 | 2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $35.33 | 2023-2025 | Qelbree, Qelbree |
| Ardelyx, INC. | $32.32 | 2024 | Ibsrela |
| Janssen Pharmaceuticals, INC | $26.53 | 2019-2020 | |
| Boston Scientific Corporation | $25.60 | 2025 | Watchman Flx |
| Ironshore Pharmaceuticals INC. | $24.21 | 2019 | |
| Astellas Pharma US INC | $20.82 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $18.43 | 2025 | Evkeeza |
| Nevro Corp. | $16.97 | 2019 | |
| Adlon Therapeutics L.P. | $16.00 | 2019 | |
| Medtronic, INC. | $14.60 | 2023 | Interstim |
| Corvista Health, INC. | $13.55 | 2025 | Corvista System |
| Amarin Pharma, INC. | $12.84 | 2019 | |
| Assertio Therapeutics, INC. | $11.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.